Please login to the form below
buprenorphine
This page shows the latest buprenorphine news and features for those working in and with pharma, biotech and healthcare.
Troubled Alkermes eyes November OK for new antipsychotic
and buprenorphine – saying that there wasn’t enough evidence to show it was clinically effective.
Latest news
-
Insys gets bankruptcy court okay for Subsys sale
a naloxone nasal spray formulation and a sublingual spray formulation of buprenorphine in development. ... The buprenorphine spray product was however rejected by the FDA last year.
-
Reckitt hammered by $1.4bn opioid settlement bill
Suboxone, which is based on the powerful opioid drug buprenorphine, is approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.
-
UK to add addiction warnings to opioids as use soars
Camurus gained EU approval for its weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of opioid dependence in November, the first approval of a long-acting treatment for opioid
-
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo
Other drugs gaining recommendation included:. Molteni Farmaceutici’s Sixmo (buprenorphine) an opioid dependence implant treatment that releases low levels of buprenorphine into the patient’s body for six months.
-
Brexit contributes to surge in generic drug prices
He says some medicines would be “particularly vulnerable" - highlighting a current shortage of pain and opioid addiction treatment Buprenorphine and antipsychotic Risperidone, arising in particular because there are no simple alternatives
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
Indivior discovered buprenorphine, sold it under the brand name Subutex to treat opioid addiction in 1996 and has since expanded its portfolio with Suboxone tablets, Suboxone Film, the monthly injectable Sublocade ... of buprenorphine that addresses the
-
Drug launches to watch in 2019
CAM2038 is an injectable solution that slowly releases buprenorphine – the most common drug used to treat opioid addiction – into the body, eliminating the need for daily dosages as well as the
-
Pharma deals during December 2012
deal? Coincidentally, the third late stage deal this month is also an analgesic, a buprenorphine implant lasting for six months for maintenance treatment of opioid dependence; the NDA was submitted in ... 335. Titan / Braeburn. Commercialisation and
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Bristol Myers Squibb announces positive trial results for treatment of MS
- FDA grants Pfizer/BioNTech’s COVID-19 vaccine emergency use authorisation for infants
- Virtual MSL/Sales training programs and events
- 6 trends shaping the future of personalized medicine
- Omnichannel strategies to revolutionize the healthcare professional experience
- The digital-first launch: the key to connected stakeholder experiences?
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Bristol Myers Squibb announces positive trial results for treatment of MS
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Roche shares new positive Ocrevus data for MS patients
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s
- Phase 3 trial initiated to evaluate AZ's Saphnelo in lupus nephritis
- New virtual health and care report from WHO and Novartis calls for ‘critical action’
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
